Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma(FLAMMINGO) | recruiting | Phase 2 | 100 | BiocadINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06783816 | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors | recruiting | N/A | 45 | Shanxi Bethune HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone(KPT-IST-391) | recruiting | Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06767254 | A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence | recruiting | — | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06690593 | Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy | recruiting | — | 2,990 | Zhujiang HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06082284 | A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method. | recruiting | — | 10,000 | Zhujiang HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06561854 | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone(FREEDOM) | recruiting | Phase 3 | 318 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | recruiting | Early Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT06698887 | A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea | recruiting | — | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05053607 | Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab | recruiting | N/A | 50 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06236373 | The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia(Survivorship) | recruiting | — | 45 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05203003 | Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.(MRD-CONFIRM) | recruiting | — | 260 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06700395 | A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma | recruiting | Phase 1 | 136 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04533217 | Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. | recruiting | N/A | 90 | Spine Centre of Southern DenmarkOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06245629 | Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | recruiting | — | 100 | Uppsala UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | recruiting | N/A | 100 | Peking University People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06588413 | Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan(FONDO-LOW) | recruiting | Phase 3 | 172 | Augusta UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06682156 | Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients | recruiting | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06644118 | A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 58 | Zhejiang UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04561557 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System(CARTinNS) | recruiting | Early Phase 1 | 36 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06659276 | Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma(MMR-PET-22-04) | recruiting | — | 83 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05546723 | LMY-920 for Treatment of Relapsed or Refractory Myeloma(LMY-920-002) | recruiting | Phase 1 | 30 | Luminary TherapeuticsINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06539832 | Intestinal Flora and Immunity in Monoclonal Gammopathy Patients | recruiting | — | 300 | Zhujiang HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06541860 | DAratumumab and REvlimid REfractory MM | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06271252 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | recruiting | Phase 1 | 81 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06515249 | Integrative Therapies in Multiple Myeloma | recruiting | N/A | 300 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06515262 | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | recruiting | N/A | 10 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06463717 | Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not | recruiting | — | 210 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | recruiting | Early Phase 1 | 10 | Shanghai Changzheng HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05248633 | Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma | recruiting | Phase 2 | 220 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06149910 | Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma | recruiting | — | 450 | All4CureINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03131531 | Bergamo Lymphoid Cancer Registry | recruiting | — | 6,000 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 15 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2025source: clinicaltrials